Mutations in the ARID1a gene, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. But this mutated gene may also strengthen specific cancer drugs’ ability to treat certain tumors, according to a team of MD Anderson researchers.
Their study, published in Cancer Discovery, discovered that certain mutations in ARID1a sensitize some tumors to PARP inhibitor drugs, such...
The costs associated with cancer drug prices have risen dramatically over the past fifteen years, which concerns many top oncologists. In...